Disulfiram
| Evidence Level: L5 | Predicted Indications: 0 |
Table of Contents
- Disulfiram
- DISULFIRAM: Drug Repurposing Assessment Report (Insufficient Data, Unable to Complete Full Analysis)
DISULFIRAM: Drug Repurposing Assessment Report (Insufficient Data, Unable to Complete Full Analysis)
One-Sentence Summary
DISULFIRAM (DB00822) is a clinically known drug used for the treatment of alcohol dependence. In this Evidence Pack, the TxGNN model returned no predicted indications, and there is missing information on mechanisms of action (MOA) and safety data; at present a formal drug repurposing assessment cannot be conducted.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not provided in Evidence Pack (field empty) |
| Predicted New Indication | None (predicted_indications empty array) |
| TxGNN Prediction Score | None |
| Evidence Level | Unable to determine (no prediction results) |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why This Evaluation Cannot Proceed
The Evidence Pack currently lacks three critical pieces of data, halting the assessment process:
1. No TxGNN Prediction Results
The predicted_indications array is empty, indicating that the TxGNN model has not yet returned candidate indications for this drug. All core analytical sections in the report (prediction rationale, clinical trial evidence, literature support) cannot be generated.
2. Mechanism of Action (MOA) Data Missing
DrugBank query has been completed (query_log shows result_status: success), but the MOA field is still marked as a Data Gap, indicating it has not yet been parsed or written to the Evidence Pack. Without MOA data, mechanism-of-action relationship analysis cannot be performed.
3. Safety Data Missing
TFDA package insert query has been completed (result_status: success), but warnings and contraindications fields have not been parsed and populated from the PDF. This is a Blocking-level Data Gap, affecting initial safety assessment.
Taiwan Market Information
DISULFIRAM is currently not marketed in Taiwan, with no drug authorization records.
Safety Considerations
Please refer to the warnings and contraindications sections of the package insert.
Note: The TFDA package insert PDF has been successfully queried (
query_logID 4), but content parsing has not yet been completed. The warnings, contraindications, and drug interactions fields must be populated in the Evidence Pack before formal safety assessment can be conducted.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence Pack lacks TxGNN prediction results, and mechanism of action and safety data have not been populated, making it impossible to conduct any substantive assessment of DISULFIRAM's drug repurposing potential.
To proceed, the following is needed:
- Execute TxGNN model prediction, generate candidate indication list for DB00822, write to
predicted_indications - Parse DrugBank query results, populate
original_moafield - Parse the obtained TFDA package insert PDF, structure and write warnings (
key_warnings) and contraindications (contraindications) to Evidence Pack - Populate
original_indications(known clinical use: alcohol dependence treatment) - After the above data is complete, regenerate Evidence Pack v5 and initiate the complete assessment workflow
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.